BRAF and non-small cell lung carcinoma: Recently, encorafenib plus binimetinib was also approved for BRAF V600E-mutant NSCLC based on the phase II PHAROS trial demonstrating an ORR of 75% in treatment-naïve patients and 46% in previously treated patients with metastatic NSCLC harboring a BRAF V600E mutation [68].